Choice of contrast media in hemodynamics and limitations of connected risks;Scelta del mezzo di contrasto per l'emodinamica e limitazione dei rischi connessi

Italian Heart Journal, Supplementi

Volumn 5, Issue 2, 2004, Pages 142-150

  Baralis, Giorgio ^a   Steffenino, Giuseppe ^a   Dellavalle, Antonio ^a   La Scala, Eugenio ^a   Uslenghi, Eugenio ^a  

^a Struttura Semplice di Emodinamica   (Italy)

Author keywords

Interventional cardiology; Quality assurance

Indexed keywords

CONTRAST MEDIUM; CREATININE;

AGE; BLOOD; CHEMICALLY INDUCED DISORDER; DEHYDRATION; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; HEALTH CARE QUALITY; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INCIDENCE; KIDNEY DISEASE; OSMOLARITY; REVIEW; RISK; RISK FACTOR; THROMBOSIS;

AGE FACTORS; CONTRAST MEDIA; CREATININE; DEHYDRATION; DISEASE SUSCEPTIBILITY; DRUG HYPERSENSITIVITY; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMANS; INCIDENCE; KIDNEY DISEASES; OSMOLAR CONCENTRATION; QUALITY ASSURANCE, HEALTH CARE; RISK; RISK FACTORS; THROMBOSIS;

EID: 77957171532     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Steffenino G, Dellavalle A, Ribichini F, et al. Quality assurance and cost control in invasive and interventional cardiology. G Ital Cardiol 1994; 24: 1055-67.
2. Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001; 11: 1267-75.
3. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997; 204: 297-312.
4. Hirshfeld JW Jr. Cardiovascular effects of iodinated contrast agents. Am J Cardiol 1990; 66: 9F-17F.
5. Missri J, Jeresaty RM. Ventricular fibrillation during coronary angiography: reduced incidence with nonionic contrast media. Cathet Cardiovasc Diagn 1990; 19: 4-7. (Pubitemid 20082222)
6. Stormorken H, Skalpe IO, Testart MC. Effect of various contrast media on coagulation, fibrinolysis, and platelet function. An in vitro and in vivo study. Invest Radiol 1986; 21: 348-54.
7. Dawson P, Hewitt P, Mackie IJ, Machin SJ, Amin S, Bradshaw A. Contrast, coagulation and fibrinolysis. Invest Radiol 1986; 21: 248-52.
8. Kopko PM, Smith DC, Bull BS. Thrombin generation in nonclottable mixtures of blood and nonionic contrast agents. Radiology 1990; 174: 459-61.
9. Parvez Z, Vik H. Intravascular contrast media and thrombin generation. Acta Radiol 1994; 35: 172-5.
10. Grines CL, Schreiber TL, Savas V, et al. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 27: 1381-6.
11. Scheller B, Hennen B, Pohl A, Schieffer H, Markwirth T. Acute and subacute stent occlusion - risk reduction by ionic contrast media. Eur Heart J 2001; 22: 385-91. (Pubitemid 32622443)
12. Aguirre FV, Simoons ML, Ferguson JJ, et al. Impact of contrast media on clinical outcomes following percutaneous coronary interventions with platelet glycoprotein IIb/IIIa inhibition: meta-analysis of clinical trials with abciximab. (abstr) Circulation 1997; 96 (Suppl 1): I-161.
13. Vacek JL, Hibiya K, Rosamond TL, et al. Anticoagulant effect of iohexol vs ioxaglate during cardiac catheterization. J Invasive Cardiol 1992; 4: 139-44.
14. Malekianpour M, Bonan R, Lesperance J, et al. Comparison of ionic and nonionic low osmolar contrast media in relation to thrombotic complications of angioplasty in patients with unstable angina. Am Heart J 1998; 135 (Part 1): 1067-75.
15. Bertrand ME, Esplugas E, Piessens J, Rasch W, for the Visipaque in Percutaneous Transluminal Coronary Angioplasty (VIP) Trial Investigators. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty. A multicenter, randomized, double-blind study. Circulation 2000; 101: 131-6.
16. Schräder R. Contrast media selection in interventional cardiology. Journal of Clinical Basic Cardiology 2001; 4: 245-8. (Pubitemid 34073352)
17. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000; 101: 2172-7.
18. Thomsen HS, Morcos SK. Radiographic contrast media. BJU Int 2000; 86 (Suppl 1): 1-10.
19. Laroche D, Aimone-Gastin I, Dubois F, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 1998; 209: 183-90.
20. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621-8.
21. Sutton AG, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J 2001; 141: 677-83.
22. Christiansen C, Pichler WJ, Skotland T. Delayed allergylike reactions to X-ray contrast media: mechanistic considerations. Eur Radiol 2000; 10: 1965-75.
23. Webb JA, Stacul F, Thomsen HS, et al, for the Members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003; 13: 181-4.
24. Rydberg J, Charles J, Aspelin P. Frequency of late allergy-like adverse reactions following injection of intravascular non-ionic contrast media. A retrospective study comparing a non-ionic monomeric contrast medium with a non-ionic dimeric contrast medium. Acta Radiol 1998; 39: 219-22.
25. Fransson SG, Stenport G, Andersson M. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate. Acta Radiol 1996; 37: 218-22.
26. Morcos SK, Thomsen HS, Webb JA, for the Contrast Media Safety Committee of the European Society of Urogenital Radiology. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol 2001; 11: 1720-8.
27. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987; 317: 845-9.
28. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. AJR Am J Roentgenol 1994; 162: 523-6.
29. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991; 87: 867-72.
30. Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41: 1274-9.
31. Manske CL, Sprafka JM, Stroni JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-20. (Pubitemid 20384319)
32. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-80.
33. Taliercio CP, Vlietstra RE, Ilstrup DM, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991; 17: 384-90.
34. Briguori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis 2003; 45: 493-503.
35. Humes HD, Hunt DA, White MD. Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol 1987; 252 (Part 2): F246-F255.
36. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75. (Pubitemid 27506242)
37. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254-61.
38. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-8.
39. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-3. (Pubitemid 29355616)
40. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, for the Nephrotoxicity in High-Risk Patients Study of Iso-osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-9.
41. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20. (Pubitemid 24348355)
42. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29-C34.
43. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36.
44. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-65.
45. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260-3.
46. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-4. (Pubitemid 30489215)
47. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553-8.
48. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303.
49. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-7.
50. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603. (Pubitemid 37013299)
51. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41: 2114-8. (Pubitemid 36724254)
52. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143: 894-903. (Pubitemid 34595351)
53. Stone GW, McCullough P, Tumlin J, et al. A prospective, randomized placebo-controlled multicenter trial evaluating fenoldopam mesylate for the prevention of contrast induced nephropathy: the CONTRAST trial. (abstr) J Am Coll Cardiol 2003; 41 (Suppl A): 83A.
54. Libby P. Metformin and vascular protection: a cardiologist's view. Diabetes Metab 2003; 29 (Part 2): S117-20.
55. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. Eur Radiol 1999; 9: 738-40.
56. Pertek JP, Vidal S, Mariot J, Galy-Floch M, Azoulay E. Metformin- associated lactic acidosis precipitated by acute renal failure. Ann Fr Anesth Reanim 2003; 22: 457-60. (Pubitemid 36851661)